Company: CRNX
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057452
Chunk: 31

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 31
---
 are valued based on the aggregate grant date fair value of the RSUs and option awards in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. See Note 11 to our consolidated financial statements in our Annual Report on Form 10‑K for the year ended December 31, 2024 filed with the SEC on February 27, 2025, for a discussion of the relevant assumptions used in determining the grant date fair value pursuant to ASC 718. These amounts do not reflect whether the recipient has actually realized or will realize a financial benefit from the awards (such as by exercising stock options). Whether, and to what extent, a non‑employee director realizes a financial benefit from the awards will depend on our stock price performance and the non‑employee director’s continued service on our board. The aggregate number of shares subject to RSUs and stock options outstanding at December 31, 2024 for each non‑employee director who served on our board of directors during 2024 was as follows:

<div align='center'>19</div>

|                              | Name |     |         Number of 
        Securities 
   Underlying RSUs 
    Outstanding at 
 December 31, 2024 |     |     |          Number of 
         Securities 
 Underlying Options 
     Outstanding at 
  December 31, 2024 |
|:-----------------------------|:-----|:----|------------------:|:----|:----|-------------------:|
| Camille Bedrosian, M.D.      |      |     |             3,400 |     |     |             90,000 |
| Caren Deardorf               |      |     |             3,400 |     |     |             69,375 |
| Matthew K. Fust              |      |     |             3,400 |     |     |             42,092 |
| Weston Nichols, Ph.D.        |      |     |             3,400 |     |     |             90,000 |
| Stephanie S. Okey, M.S.      |      |     |             3,400 |     |     |             85,000 |
| Rogério Vivaldi Coelho, M.D. |      |     |             3,400 |     |     |             73,750 |
| Wendell Wierenga, Ph.D.      |      |     |             3,400 |     |     |             90,